Phase II trial of ALG 1001 in patients with wet age-related macular degeneration.
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2013
Price : $35 *
At a glance
- Drugs Risuteganib (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Allegro Ophthalmics
- 10 Oct 2013 New trial record
- 09 Oct 2013 The FDA has approved the IND to start this trial, according to an Allegro Ophthalmics media release.